T® from the pivotal Precision-T Phase 3 study will be presented including quality of life and rates of rehospitalizations compared to conventional alloHSCTData evaluating the use of Orca-T with ...
Genetix delivers strong 2025 revenue growth resulting in the Company’s first ever profitable quarterIn 2025, >100 U.S. patients were treated and >150 U.S. patients completed their first cell ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results